drugset
drugset / Trial / NCT03900676

Efficacy and Safety Study of VB-1953 Topical Gel for Inflammatory Facial Acne Vulgaris

NCT03900676 ↗

Phase 2 Unknown 480 enrolled Vyome Therapeutics Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Dose-ranging Study in the Treatment of Acne Vulgaris,

Timeline

Start
2019-04-09
Primary completion
2019-11
Completion
2020-03

Drugs

EvaluationDrugModalityDoseRoute
Subject VB-1953 Unknown 2 % Topical

Indications

acne